Abstract: The present disclosure relates generally to compositions, dosage forms, and methods for preventing and treating infections. The compositions include intact and substantially non-viable Gram-negative bacterial cells which have been treated to reduce lipopolysaccharide (LPS)-associated endotoxin activity, which surprisingly have increased activity to trigger immune cell production of cytokines.

Abstract: The present invention pertains to a vaccine comprising in combination an IgM protease antigen of Streptococcus suis and a Streptococcus suis bacterin of serotype (9), sequence type (16), for use in a method for protecting pigs against a pathogenic infection with Streptococcus suis serotype (9), sequence type (16).

Abstract: Technologies for the prevention and/or treatment of pneumococcal infections.

Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor (TNF)-like ligand (TL1A). The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.

Abstract: The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., breast cancer). It relates to mutant phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-targeted T cell receptors (TCRs) that specifically target a mutant PIK3CA peptide (e.g., a human mutant PIK3CA peptide), and immunoresponsive cells comprising such TCRs. The presently disclosed mutant PIK3CA peptide-specific TCRs have enhanced immune-activating properties, including anti-tumor activity.

Abstract: The present disclosure relates to a method of treating an acute inflammatory disorder such as septic shock in a subject in need thereof. The method involves administering to a subject who has a soluble TREM-1 (sTREM-1) level measured in a biological sample from the subject greater than a predetermined sTREM-1 value an amount of a TREM-1 inhibitor sufficient to treat the inflammatory disorder.

Abstract: The present invention provides a Bacillus subtilis strain selected from the group consisting of a) the strain deposited as DSM32324,b) the strain deposited as DSM32325, and c) a mutant strain of (a) or (b) which has sensitivity for ampicillin, vancomycin, gentamicin, kanamycin, streptomycin, erythromycin, clindamycin, tetracycline, and chloramphenicol; and has inhibitory activity against E. coli and Clostridium perfringens. The invention further relates to Bacillus compositions comprising at least one Bacillus subtilis strain of the invention, preferably the Bacillus subtilis strain DSM32324 and/or the Bacillus subtilis strain DSM32325, as Direct Fed Microbial (DFM), premix, animal feed additive or animal feed.

Abstract: A protein molecule that includes interleukin 12a (IL12a), interleukin 12b (IL12b), a first factor and a second factor located in the same polypeptide chain that can be used for treating tumors.

Abstract: Provided are delivery immunostimulatory bacteria that have enhanced colonization of tumors, the tumor microenvironment and/or tumor-resident immune cells, and enhanced anti-tumor activity. The immunostimulatory bacteria are modified by deletion of genes encoding the flagella, or by modification of the genes so that functional flagella are not produced, and/or are modified by deletion of pagP or modification of pagP to produce inactive PagP product. As a result, the immunostimulatory bacteria are flagellin? and/or pagP?. The immunostimulatory bacteria optionally have additional genomic modifications so that the bacteria are adenosine or purine auxotrophs. The bacteria optionally are one or more of asd?, purI?, and msbB?.

Abstract: Various embodiments of the present invention are directed to the field of treating and preventing osteoporosis, with particular embodiments directed to a method of ameliorating, treating, or preventing osteoporosis in a human subject employing tomatidine, xylitol, rapamycin, etc., as well as modifying an individual's microbiome to reduce the likelihood of osteoporosis.

Abstract: Provided herein are glycoproteins containing O-linked glycosylation recognition motifs, and methods of making, for example, for use in the production of conjugate vaccines.

Abstract: A spore-forming Bacillus species, and more particularly, a Bacillus velezensis strain identified as BV379 is provided. Compositions comprising BV379 and methods of using the same are also provided.

Abstract: Provided are conjugates of an arginine deiminase (ADI) and a Tumor Necrosis Factor (TNF) superfamily ligand, and related compositions and methods of use thereof. Also provided are conjugates of a hexameric polypeptide and a trimeric polypeptide, conjugates of a first and second trimeric polypeptide, and related compositions and methods of use thereof.

Abstract: An immunogenic composition comprising a deletion mutant of a Clostridioides difficile TcdB toxin (such as TcdB2 or TcdB1) that lacks residues at least from amino acid residue 1769 to amino acid residue 1787 of a wild-type TcdB amino acid sequence or of a protein having high identity thereto, a vaccine comprising the immunogenic composition, a method of stimulating an immune response, a nucleic acid which encodes the amino acid sequence of the deletion mutant, a vector encoding the nucleic acid, and a host cell comprising the vector.

Abstract: An anti-CD47 monoclonal antibody and use thereof. The provided anti-CD47 monoclonal antibody can effectively inhibit tumor growth. Blocking human SIRP and human CD47 signals may enhance macrophage phagocytosis of tumor cells, prevent the tumor cells from escaping a tumor immune defense system, and have an anti-tumor function. Blocking association between the CD47 on a tumor cell surface and the SIRP on a macrophage surface may block a “do not eat me” signal from the tumor cells, promoting tumor cell recognition and uptake of macrophages, and thereby facilitating tumor cells to be phagocytosed. The association between the CD47 on a tumor cell surface and the SIRP on a macrophage surface is a common “do not eat me” signal. The anti-CD47 antibody, as a very promising target in the tumor immune system, will play a powerful and effective role in human cancer therapy.

Abstract: Disclosed herein are interleukin (IL)-15 conjugates and use in the treatment of one or more indications. Also described herein include pharmaceutical compositions and kits comprising one or more of IL-15 conjugates. In some embodiments, at least one amino acid residue in the IL-15 conjugate is replaced by the structure of Formula (I) described herein.

Abstract: The invention comprises a defined and safe soil substitute, herein referred to as “deconstructed soil”, that supports ecological balance in anaerobic microbial ecosystems, such as that inside the human gut, by shifting energy availability to favor growth of bacteria linked with gut health, and away from the most dominant species and species that are putatively harmful. The invention enables vulnerable bacterial groups to recover from a state of apparent extinction from the ecosystem in question. As it does not contain components that are prebiotic or probiotic, the deconstructed soil represents a new product concept for preventing and treating conditions associated with dysfunctional microbial ecosystems in the gastrointestinal tract of humans and animals, as well as other anaerobic microbial ecosystems.

Abstract: Compositions, systems and methods of improving the health of the microbiome of an individual's skin relate to the provision of skin contacting formulations containing beneficial bacteria and other microbe components to foster the growth and maintenance of a healthy skin microbiome. Certain embodiments include methods of treatment for acne and other skin disorders involving the use of probiotics, as well as the use of bacteria engineered via CRISPR systems for the treatment of specific skin disorders.

Abstract: The present invention provides a novel modified chemokine peptide. Additionally, the novel modified chemokine peptide can be used to treat cancer and inhibit tumor growth more effectively.

Abstract: An anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate or a pharmaceutically acceptable salt thereof, and an application of the anti-HER2 antibody-drug conjugate for preparing an antitumor 5 pharmaceutical product.